

Form PTO-1449 U.S. Department of Commerce  
(REV. 2-82) Patent and Trademark Office

Atty. Docket No.  
A31909-PCT-USA (072874.0153)


Serial No.  
09/848,948

INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT  
(Use several sheets if necessary)

Applicants  
Hanash et al.

Filing Date  
May 4, 2001

Group Art Unit  
1642



SEARCHED INDEXED  
OCT 10 2003

U.S. PATENT DOCUMENTS

*Exam. Init.	Document No.							Date	Name	Class	Subclass	Filing Date if Appropriate
SR	5	4	0	5	7	4	9	04/11/95	Polans et al.			
↓	5	3	5	0	6	8	7	09/27/94	Odink et al.			RECEIVED
												OCT 17 2003
												TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENT

	Document No.							Date	Country	Class	SubClass	Translator Yes No
SR	9	8	3	7	4	2	0	08/27/98	WO			
↓	9	8	3	5	9	8	5	08/20/98	WO			
	9	8	0	1	4	7	1	01/15/98	WO			
	2	0	4	5	7	5	9	10/10/95	RU			
↓	0	5	8	5	2	0	1	03/02/94	EP			

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

SR		Mochizuki et al., (1999) "Possession System: Middleware for Adaptive Multiuser Applications in a Mobile Environment", IEEE: 198-205.
↓		Karnell et al. (1997) "S100B protein, 5-S-cysteinyl-dopa and 6-hydroxy-%-methoxyindole-2-carboxylic acid as biochemical markers for survival prognosis in patients with malignant melanoma," Melanoma Research, 7:393-399
		Hansson et al., (1997) "Prognostic Value of Serum Analyses of S-100 Protein B in Malignant Melanoma", Anticancer Research, 17: 3071-3074.
		E. von Schoultz et al., (1996) "Prognostic value of serum analyses of S-100B protein in malignant melanoma", Melanoma Research, vol. 6: 133-137.
↓		Merzak et al., (1994), "Overexpression of the <i>18A2/mts1</i> gene and down-regulation of the TIMP-2 gene in invasive human glioma cell lines <i>in vitro</i> ", Neuropathol App. Neurobiol. 20: 614-619.

Examiner

Date Considered

6/1/05

\* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.  
NY02:458672.1

<p>Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use several sheets if necessary)</p> <p><i>614</i></p> <p>OCT 10 2003</p>		<p>Atty. Docket No. A31909-PCT-USA (072874.0153)</p> <p>Serial No. 09/848,948</p>	
<p>Applicants Hanash et al.</p>		<p>Filing Date May 4, 2001</p>	<p>Group Art Unit 1642</p>

## U.S. PATENT DOCUMENTS

**FOREIGN PATENT DOCUMENT**

**OTHER DOCUMENTS** (including Author, Title, Date, Pertinent Pages, Etc.)

REFERENCES (including Author, Title, Date, Pertinent Pages, Etc.)		
52		Inoue et al., (1993) "Distribution of S-100 protein-positive dendritic cells and expression of HLA-DR antigen in transitional cell carcinoma of the urinary bladder in relation to tumour progression and prognosis", <i>Virchows Arch A Pathol Anat</i> 422: 351-355.
		Butler, J.E., (1981) "The amplified ELISA: Principles of and Applications for the Comparative Quantitation of Class and Subclass Antibodies and the Distribution of Antibodies and Antigens in Biochemical Separates", <i>Meth. Enzymol</i> 73: 482-523.
↓		Voller et al., (1978) "Enzyme immunoassays with special reference to ELISA techniques", <i>J. Clin. Pathol.</i> , 31: 507-520.

---

**Examiner**

**Date Considered**

CT1105

\* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.  
NY02:458672.1